DPYSL5 and neoplasm: PNS can emerge with tumor recurrence [6], and cases have been reported where PNS phenotype and anti-neuronal antibodies differed between initial diagnosis and recurrence (e.g., anti-recoverin retinopathy at diagnosis vs. anti-CV2/CRMP5 myelitis at recurrence) [19].